KRAS G12D

January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer. The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan—two main components commonly used in pancreatic cancer treatments—when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer. Moreover, synergistic activity was also observed with the chemotherapeutic agent gemcitabine. This promising synergistic activity was observed after the confluence of these tumor cell lines, reflecting how SIL-204 may enhance the effects of 5-fluorouracil and irinotecan when used together, as well as that of gemcitabine. For example, in preclinical models, the combination of 5-fluorouracil and irinotecan with SIL-204 led to a significant reduction in cancer cell confluence after about three days compared to treatment with the chemotherapy agents alone (p This comes on top of previous recent announcements from Silexion regarding pre-clinical findings from the ongoing development of SIL-204, in line with earlier successes with the company’s first-generation product, LODER™ (siG12DLoder), which showed a significant improvement in overall survival in the siRNA plus chemotherapy arm compared to chemotherapy alone in Phase 2 trials. “These new findings, combined with the substantial milestones we have recently reported in developing SIL-204, suggest that Silexion’s approach could potentially revolutionize the treatment landscape not only for pancreatic cancer but also for a wide range of KRAS-mutated cancers, which remain some of the most difficult to treat. The synergy demonstrated between SIL-204 and first-line chemotherapies underscores its potential to enhance existing treatment regimens and address significant unmet needs across multiple oncology indications,” said Ilan Hadar, Chairman and CEO of Silexion. As previously reported, Silexion is gearing up for the clinical development of SIL-204, Planning to initiate toxicology studies with SIL-204 within the upcoming months and to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC) which has a notoriously high mortality rate. In parallel, the company plans to initiate preclinical studies for SIL-204, in colorectal cancer models. Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com The content above comes from the network. if any infringement, please contact us to modify.

NEW YORK--( BUSINESS WIRE )-- PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate. These findings reaffirm the company’s innovative approach to addressing some of the most challenging cancers, including pancreatic cancer, which is marked by KRAS mutations in over 90% of cases. The newly released data reveal significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine. In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy of these standard therapies, resulting in greater reductions in cancer cell confluence compared to chemotherapy alone. This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven cancers, potentially addressing a substantial unmet medical need. Building on the success of its first-generation LODER™ platform, which improved overall survival in Phase 2 trials, SIL-204 takes Silexion’s RNAi approach further by targeting a broader spectrum of KRAS mutations. With toxicology studies set to begin soon and Phase 2/3 trials planned for 2026, Silexion remains on track to advance its groundbreaking candidate into the clinic. Shortly releasing this new data, Silexion also announced the pricing of a $5 million public offering to support its preclinical and clinical efforts. While this may introduce near-term dilution, if the offering is to close, the additional capital seems to bolster the company’s ability to drive innovation and achieve key clinical milestones as it moves forward. As KRAS-driven cancers continue to be among the most aggressive and elusive to treat, Silexion’s progress with SIL-204 positions it as an important innovator to watch in the precision oncology space, offering hope for transformative therapies that could redefine cancer care. Subscribe for more updates from PESG: https://www.pesgresearch.com/subscribe PESG is a commercial digital news and coverage brand. PESG’s market updates are intended to summarize news developments from issuers it engages with and thus include partner advertising content on behalf of the mentioned issuer [SLXN]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here : redditwire.com/terms. PESG is part of the Wall Street Wire network, which is operated by an IR provider for commercial purposes. Our content may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.

BOSTON--( BUSINESS WIRE )--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company’s executive leadership team. “ We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance our clinical programs,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “ Matt is an accomplished biopharmaceutical executive with extensive experience driving business transformation. His expertise will drive invaluable operational excellence as we prepare to launch a potential first-in-class treatment combination for patients with low-grade serous ovarian cancer, a rare cancer with no approved treatments specifically for this disease, and simultaneously progress programs and partnerships to address cancers driven by the RAS/MAPK-pathway that often lack treatment options.” Mr. Ros brings more than 35 years of commercialization and operational experience in the biopharmaceutical industry with a track record of capital-driving success at publicly traded biopharmaceutical companies undergoing evolutions from early stage to registrational development. Most recently, Mr. Ros served as chief executive officer and board director at FORE Biotherapeutics, an early, clinical-stage oncology company focused on recurrent central nervous system malignancies. Previously, Mr. Ros held executive leadership roles at prominent biopharmaceutical companies, including Epizyme, Sanofi-Genzyme, and ARIAD Pharmaceuticals, where he built fully integrated commercial organizations, delivered strategic collaborations, secured multiple FDA approvals, and supported successful launches. Mr. Ros began his career at Bristol-Myers Squibb where he held positions of increasing responsibility within its Oncology division, contributing to and championing the successful launches of many leading oncology brands. In addition to his executive experience, Mr. Ros serves as a board member at Cogent Biosciences, contributing to its Audit, Nomination, and Governance Committees, and previously served on the Board of Trustees of CancerCARE. “ My life’s work has been focused on fostering the growth and operational strength of companies dedicated to changing cancer and improving the lives of people living with cancer,” said Mr. Ros. “ I am excited to be joining Verastem Oncology to help build on the company’s momentum and create tremendous opportunities for the future while having the potential to bring a meaningful new treatment option to women living with a rare ovarian cancer.” About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn .